The Risks and Opportunities of Homeostatic Repopulation
稳态增殖的风险和机遇
基本信息
- 批准号:10622054
- 负责人:
- 金额:$ 327.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-15 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAffectAlloantigenAnimal ModelAntibodiesAntithymoglobulinAwardB cell repertoireB-Cell Antigen ReceptorB-LymphocytesBiological AssayBiologyCardiovascular DiseasesCause of DeathCessation of lifeChronicClinical TrialsCollaborationsCytomegalovirus InfectionsDataDrug CombinationsEnd stage renal failureEvaluationFundingFutureGeneticGenetic IdentityGoalsGrantHealthHelper-Inducer T-LymphocyteHumanIL2 geneImmuneImmune ToleranceImmune responseImmunologyImmunosuppressionImmunosuppressive AgentsIndividualIndolentIndustry CollaborationInfectionInfusion proceduresKidney FailureKidney TransplantationLearningLettersLongevityMacacaMacaca mulattaMalignant NeoplasmsMeasuresMediatingMemory B-LymphocyteMethodologyModelingNational Institute of Allergy and Infectious DiseaseOperative Surgical ProceduresOrgan TransplantationPathway interactionsPatientsPharmaceutical PreparationsPopulationPublishingQuality of lifeRegulationRegulatory T-LymphocyteResearchRiskSafetySirolimusStructure of germinal center of lymph nodeT-LymphocyteTherapeutic immunosuppressionTrainingTranslatingTransplant RecipientsTransplantationUnited StatesUnited States National Institutes of HealthWorkallotransplantantibody-mediated rejectioncareerexperienceimmunological interventionimprovedinsightisoimmunitylymph nodesnonhuman primatenovelnovel strategiesnovel therapeuticspharmacologicpreventresponsetooltransplant modeltransplantation medicinevirtual
项目摘要
ABSTRACT – Overall
The NHP kidney transplant model offers unique and important pathways to the improved understanding and
implementation of novel therapies for human transplant patients. Being an outbred, large animal model with
close genetic similarities to humans allows more accurate modeling of mechanisms and drugs/drug
combinations, and virtually all recently approvedimmunosuppressive agents and strategies have beenevaluated
in a NHP model. Our group has contributed to these advances substantially for approximately three decades,
resulting in over five clinical trials arising from our NHP research. Now we propose to focus on novel strategies
to promote donor-specific tolerance, to further develop our understanding of the interrelationship between CMV
infection and alloimmunity, and to advance our strategies for addressing the T and B cell response to
alloantigens. We have developed a collaboration that allows us to interrogate the T cell and B cell receptor
repertoire of macaques and their changes in response to immune interventions. This novel tool will greatly
enhance our ability to measure the impact of therapies at the cellular level in rhesus monkeys. In addition, we
have pioneered methodologies to assess the immune response within lymph nodes of rhesus monkeys and
measure germinal center changes and changes of T follicular helper cells as a means of better understanding
the B cell response to allotransplantation. We plan to use our collective experience in rhesus monkey kidney
transplantation and biology to evaluate therapies that are translatable to human kidney transplantation and will
also use mechanistic assays that can be performed in humans. In addition to the translational benefits of the
proposed work such as donor-specific regulatory T cell augmentation, we expect to gain fundamental new
insights into B cell memory durability and the breadth of T and B cell repertoires to alloantigens and how these
change with therapy and during rejection or infection. Our proposal involves many academic and industry
collaborations that are ongoing as attested by letters of support. We will continue to train individuals who plan
careers in transplant medicine, surgery, and immunology such that they will be prepared to lead the future of our
field. The impact of this proposal has broad implications that may benefit U.S. citizens affected by end stage
renal failure or by immune-mediated illnesses or infections.
摘要-总体
项目成果
期刊论文数量(12)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model.
- DOI:10.1016/j.kint.2020.08.020
- 发表时间:2021-01
- 期刊:
- 影响因子:19.6
- 作者:Schroder PM;Schmitz R;Fitch ZW;Ezekian B;Yoon J;Choi AY;Manook M;Barbas A;Leopardi F;Song M;Farris AB;Collins B;Kwun J;Knechtle SJ
- 通讯作者:Knechtle SJ
Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient.
先天网络:血栓性微血管病,凝血和补体在敏化肾脏移植受体中的激活。
- DOI:10.1016/j.trre.2018.01.001
- 发表时间:2018-07
- 期刊:
- 影响因子:0
- 作者:Manook M;Kwun J;Sacks S;Dorling A;Mamode N;Knechtle S
- 通讯作者:Knechtle S
Targeting Calcium Release-activated Calcium Channel Is Not Sufficient to Prevent Rejection in Nonhuman Primate Kidney Transplantation.
靶向钙释放激活的钙通道不足以防止非人灵长类肾移植中的排斥反应。
- DOI:10.1097/tp.0000000000003078
- 发表时间:2020
- 期刊:
- 影响因子:6.2
- 作者:Kwun,Jean;Ezekian,Brian;Manook,Miriam;Park,Jaeberm;Yoon,Janghoon;Freischlag,Kyle;Song,Mingqing;Farris,AltonB;Sloan-Lancaster,Joanne;Fortier,Caroline;Rao,PatriciaE;Knechtle,StuartJ
- 通讯作者:Knechtle,StuartJ
Experimental modeling of desensitization: What have we learned about preventing AMR?
- DOI:10.1111/ajt.15873
- 发表时间:2020-06
- 期刊:
- 影响因子:0
- 作者:Kwun J;Knechtle S
- 通讯作者:Knechtle S
The past, present, and future of costimulation blockade in organ transplantation.
器官移植中共刺激阻断的过去、现在和未来。
- DOI:10.1097/mot.0000000000000656
- 发表时间:2019
- 期刊:
- 影响因子:2.2
- 作者:Schroder,PaulM;Fitch,ZacharyW;Schmitz,Robin;Choi,AshleyY;Kwun,Jean;Knechtle,StuartJ
- 通讯作者:Knechtle,StuartJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stuart Johnston Knechtle其他文献
Stuart Johnston Knechtle的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stuart Johnston Knechtle', 18)}}的其他基金
Targeting the B Cell Response to Treat Antibody-Mediated Rejection
靶向 B 细胞反应来治疗抗体介导的排斥反应
- 批准号:
10636822 - 财政年份:2021
- 资助金额:
$ 327.57万 - 项目类别:
Targeting the B Cell Response to Treat Antibody-Mediated Rejection
靶向 B 细胞反应来治疗抗体介导的排斥反应
- 批准号:
10472725 - 财政年份:2021
- 资助金额:
$ 327.57万 - 项目类别:
Targeting the B Cell Response to Treat Antibody-Mediated Rejection
靶向 B 细胞反应来治疗抗体介导的排斥反应
- 批准号:
10283031 - 财政年份:2021
- 资助金额:
$ 327.57万 - 项目类别:
The Risks and Opportunities of Homeostatic Repopulation
稳态增殖的风险和机遇
- 批准号:
9751206 - 财政年份:2017
- 资助金额:
$ 327.57万 - 项目类别:
The Risks and Opportunities of Homeostatic Repopulation
稳态增殖的风险和机遇
- 批准号:
9980776 - 财政年份:2017
- 资助金额:
$ 327.57万 - 项目类别:
Depletion, Repopulation and Tolerance in Sensitized Recipients
致敏受体的消耗、再生和耐受性
- 批准号:
10649946 - 财政年份:2017
- 资助金额:
$ 327.57万 - 项目类别:
Depletion, Repopulation and Tolerance in Sensitized Recipients
致敏受体的消耗、再生和耐受性
- 批准号:
9980792 - 财政年份:2017
- 资助金额:
$ 327.57万 - 项目类别:
Depletion, Repopulation and Tolerance in Sensitized Recipients
致敏受体的消耗、再生和耐受性
- 批准号:
10214496 - 财政年份:2017
- 资助金额:
$ 327.57万 - 项目类别:
The Risks and Opportunities of Homeostatic Repopulation
稳态增殖的风险和机遇
- 批准号:
10518424 - 财政年份:2017
- 资助金额:
$ 327.57万 - 项目类别:
The Risks and Opportunities of Homeostatic Repopulation
稳态增殖的风险和机遇
- 批准号:
10214492 - 财政年份:2017
- 资助金额:
$ 327.57万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 327.57万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 327.57万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 327.57万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 327.57万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 327.57万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 327.57万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 327.57万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 327.57万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 327.57万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 327.57万 - 项目类别:
Research Grant














{{item.name}}会员




